Comparative response of platelet fV and plasma fV to activated protein C and relevance to a model of acute traumatic coagulopathy

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Campbell, James E ^a   Meledeo, Michael Adam ^a   Cap, Andrew P ^a  

^a United States Army Institute of Surgical Research Coagulation and Blood Research Program JBSA FT Sam Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; DROTRECOGIN; ENDOTHELIAL PROTEIN C RECEPTOR; FIBRIN; PHOSPHOLIPID; TISSUE PLASMINOGEN ACTIVATOR; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; CELL SURFACE RECEPTOR; LEUKOCYTE ANTIGEN; PROCR PROTEIN, HUMAN; PROTEIN C;

ACUTE TRAUMATIC COAGULOPATHY; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; CONCENTRATION RESPONSE; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNATIONAL NORMALIZED RATIO; PLASMA; PLASMA FV; PLATELET FVA; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTHROMBIN TIME; SIMULATION; STEADY STATE; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; TURBIDIMETRY; ACUTE DISEASE; BIOLOGICAL MODEL; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; METABOLISM; PHOTOMETRY; PROTEIN DEGRADATION; SOLUBILITY;

ACUTE DISEASE; ANTICOAGULANTS; ANTIGENS, CD; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; FACTOR V; FACTOR VA; FACTOR VIII; FIBRIN; FIBRINOLYSIS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MODELS, BIOLOGICAL; NEPHELOMETRY AND TURBIDIMETRY; PHOSPHOLIPIDS; PROTEIN C; PROTEOLYSIS; PROTHROMBIN TIME; RECEPTORS, CELL SURFACE; SOLUBILITY; THROMBELASTOGRAPHY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84903388532     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099181     Document Type: Article

References (70)

1. Gando S, Wada H, Thachil J (2013) Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS). J Thromb Haemost 11: 826-835.
2. Bouillon B, Brohi K, Hess JR, Holcomb JB, Parr MJ, et al. (2010) Educational Initiative on Critical Bleeding in Trauma: Chicago, July 11-13, 2008. J Trauma 68: 225-230.
3. Brohi K, Cohen MJ, Davenport RA (2007) Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care 13: 680-685. (Pubitemid 350059533)
4. Hess JR, Brohi K, Dutton RP, Hauser CJ, Holcomb JB, et al. (2008) The coagulopathy of trauma: a review of mechanisms. J Trauma 65: 748-754.
5. Pidcoke HF, Aden JK, Mora AG, Borgman MA, Spinella PC, et al. (2012) Ten-year analysis of transfusion in Operation Iraqi Freedom and Operation Enduring Freedom: increased plasma and platelet use correlates with improved survival. J Trauma Acute Care Surg 73: S445-452.
6. Cohen MJ, Bir N, Rahn P, Dotson R, Brohi K, et al. (2009) Protein C depletion early after trauma increases the risk of ventilator-associated pneumonia. J Trauma 67: 1176-1181.
7. Brohi K, Singh J, Heron M, Coats T (2003) Acute traumatic coagulopathy. J Trauma 54: 1127-1130. (Pubitemid 36764882)
8. Brohi K, Cohen MJ, Ganter MT, Schultz MJ, Levi M, et al. (2008) Acute coagulopathy of trauma: Hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma 64: 1211-1217. (Pubitemid 351671214)
9. Chesebro BB, Rahn P, Carles M, Esmon CT, Xu J, et al. (2009) Increase in activated protein C mediates acute traumatic coagulopathy in mice. Shock 32: 659-665.
10. Cohen MJ, Call M, Nelson M, Calfee CS, Esmon CT, et al. (2012) Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. Ann Surg 255: 379-385.
11. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT (1996) The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci U S A 93: 10212-10216. (Pubitemid 26314601)
12. van 't Veer C, Golden NJ, Kalafatis M, Mann KG (1997) Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem 272: 7983-7994. (Pubitemid 27137362)
13. Hockin MF, Kalafatis M, Shatos M, Mann KG (1997) Protein C activation and factor Va inactivation on human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 17: 2765-2775. (Pubitemid 28016020)
14. Campbell JE, Brummel-Ziedins KE, Butenas S, Mann KG (2010) Cellular regulation of blood coagulation: a model for venous stasis. Blood 116: 6082-6091.
15. Panteleev MA, Ovanesov MV, Kireev DA, Shibeko AM, Sinauridze EI, et al. (2006) Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys J 90: 1489-1500.
16. Taylor FB, Jr., Lockhart MS (1985) Whole blood clot lysis: in vitro modulation by activated protein C. Thromb Res 37: 639-649.
17. Taylor FB, Jr., Lockhart MS (1985) A new function for activated protein C: activated protein C prevents inhibition of plasminogen activators by releasate from mononuclear leukocytes-platelet suspensions stimulated by phorbol diester. Thromb Res 37: 155-164.
18. Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, et al. (2007) Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? Ann Surg 245: 812-818. (Pubitemid 46684113)
19. Bajzar L, Nesheim ME, Tracy PB (1996) The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 88: 2093-2100. (Pubitemid 26307911)
20. Mosnier LO (2011) Platelet Factor 4 Inhibits Thrombomodulin-dependent Activation of Thrombin-activatable Fibrinolysis Inhibitor (TAFI) by Thrombin. Journal of Biological Chemistry 286: 502-510.
21. Urano T, Castellino FJ, Ihara H, Suzuki Y, Ohta M, et al. (2003) Activated protein C attenuates coagulation-associated over-expression of fibrinolytic activity by suppressing the thrombin-dependent inactivation of PAI-1. J Thromb Haemost 1: 2615-2620.
22. Griffin JH, Fernandez JA, Gale AJ, Mosnier LO (2007) Activated protein C. J Thromb Haemost 5 Suppl 1: 73-80. (Pubitemid 46958820)
23. Macias WL, Dhainaut JF, Yan SC, Helterbrand JD, Seger M, et al. (2002) Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 72: 391-402. (Pubitemid 35178865)
24. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, et al. (2003) Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 90: 642-653. (Pubitemid 37287632)
25. Cornet AD, Hofstra JJ, Vlaar AP, Tuinman PR, Levi M, et al. (2013) Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome. J Thromb Haemost 11: 894-901.
26. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals. J Biol Chem 270: 20794-20800.
27. Camire RM, Kalafatis M, Simioni P, Girolami A, Tracy PB (1998) Platelet-derived factor Va/Va Leiden cofactor activities are sustained on the surface of activated platelets despite the presence of activated protein C. Blood 91: 2818-2829. (Pubitemid 28227532)
28. Gould WR, Silveira JR, Tracy PB (2004) Unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor: characterization of purified platelet-derived factor V/Va. J Biol Chem 279: 2383-2393. (Pubitemid 38114221)
29. Duckers C, Simioni P, Spiezia L, Radu C, Dabrilli P, et al. (2010) Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms. Blood 115: 879-886.
30. Zivelin A, Gitel S, Griffin JH, Xu X, Fernandez JA, et al. (1999) Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C. Blood 94: 895-901. (Pubitemid 29361819)
31. Cushman M, Costantino JP, Bovill EG, Wickerham DL, Buckley L, et al. (2003) Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br J Haematol 120: 109-116. (Pubitemid 36056917)
32. Schuepbach RA, Feistritzer C, Brass LF, Riewald M (2008) Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. Blood 111: 2667-2673.
33. Gale AJ, Cramer TJ, Rozenshteyn D, Cruz JR (2008) Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V. J Biol Chem 283: 16355-16362.
34. Cramer TJ, Griffin JH, Gale AJ (2010) Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va. Pathophysiol Haemost Thromb 37: 17-23.
35. Mustard JF, Perry DW, Ardlie NG, Packham MA (1972) Preparation of suspensions of washed platelets from humans. Br J Haematol 22: 193-204.
36. Wolberg AS, Gabriel DA, Hoffman M (2002) Analyzing fibrin clot structure using a microplate reader. Blood Coagul Fibrinolysis 13: 533-539.
37. Tracy PB, Eide LL, Bowie EJ, Mann KG (1982) Radioimmunoassay of factor V in human plasma and platelets. Blood 60: 59-63. (Pubitemid 12085920)
38. Foley JH, Butenas S, Mann KG, Brummel-Ziedins KE (2012) Measuring the mechanical properties of blood clots formed via the tissue factor pathway of coagulation. Anal Biochem 422: 46-51.
39. Butenas S, Branda RF, van't Veer C, Cawthern KM, Mann KG (2001) Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 86: 660-667. (Pubitemid 32743282)
40. Kurosawa S, Stearns-Kurosawa DJ, Carson CW, D'Angelo A, Della Valle P, et al. (1998) Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 91: 725-727. (Pubitemid 28053403)
41. Liaw PC, Neuenschwander PF, Smirnov MD, Esmon CT (2000) Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J Biol Chem 275: 5447-5452. (Pubitemid 30115177)
42. Lenting PJ, van Mourik JA, Mertens K (1998) The life cycle of coagulation factor VIII in view of its structure and function. Blood 92: 3983-3996. (Pubitemid 28544310)
43. Lenting PJ, CJ VANS, Denis CV (2007) Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 5: 1353-1360.
44. Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC (1980) The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 255: 274-283. (Pubitemid 10146055)
45. Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D (1996) Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 384: 66-68. (Pubitemid 26374587)
46. Duckers C, Simioni P, Spiezia L, Radu C, Gavasso S, et al. (2008) Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 112: 3615-3623.
47. Gruber A, Griffin JH, Harker LA, Hanson SR (1989) Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood 73: 639-642. (Pubitemid 19069161)
48. Gruber A, Harker LA, Hanson SR, Kelly AB, Griffin JH (1991) Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation 84: 2454-2462.
49. D'Angelo A, Lockhart MS, D'Angelo SV, Taylor FB, Jr. (1987) Protein S is a cofactor for activated protein C neutralization of an inhibitor of plasminogen activation released from platelets. Blood 69: 231-237. (Pubitemid 17007102)
50. Komissarov AA, Andreasen PA, Declerck PJ, Kamikubo Y, Zhou A, et al. (2008) Redirection of the reaction between activated protein C and a serpin to the substrate pathway. Thromb Res 122: 397-404. (Pubitemid 351888885)
51. Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, et al. (2001) Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 85: 639-646. (Pubitemid 32293699)
52. Perez-Casal M, Downey C, Fukudome K, Marx G, Toh CH (2005) Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood 105: 1515-1522. (Pubitemid 40223668)
53. Perez-Casal M, Thompson V, Downey C, Welters I, Wyncoll D, et al. (2011) The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis. Crit Care 15: R195.
54. Solymoss S, Nguyen KT (1993) Plasma factor V activation is prevented by activated protein C in the presence of phospholipid vesicles, not platelets. Thromb Haemost 69: 124-129. (Pubitemid 23041181)
55. Lozano M, Escolar G, Schwarz HP, Hernandez R, Bozzo J, et al. (1996) Activated protein C inhibits thrombus formation in a system with flowing blood. Br J Haematol 95: 179-183. (Pubitemid 26340248)
56. Schuerholz T, Friedrich L, Marx G, Kornau I, Sumpelmann R, et al. (2007) Effect of Drotrecogin alfa (activated) on platelet receptor expression in vitro. Platelets 18: 373-378. (Pubitemid 47123840)
57. Kaiser B, Jeske W, Hoppensteadt DH, Walenga JM, Drohan W, et al. (1997) In vitro studies on the effect of activated protein C on platelet activation and thrombin generation. Thromb Res 87: 197-204. (Pubitemid 27355991)
58. Koestenberger M, Gallistl S, Muntean W, Leschnik B, Fritsch P, et al. (2005) Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma. Thromb Haemost 94: 69-74. (Pubitemid 40974707)
59. Kim PY, Nesheim ME (2010) Down regulation of prothrombinase by activated protein C during prothrombin activation. Thromb Haemost 104: 61-70.
60. Bravo MC, Orfeo T, Mann KG, Everse SJ (2012) Modeling of human factor Va inactivation by activated protein C. BMC Syst Biol 6: 45.
61. Taylor FB, Jr., Peer GT, Lockhart MS, Ferrell G, Esmon CT (2001) Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 97: 1685-1688. (Pubitemid 32217234)
62. Carey JS (1973) Physiological hemodilution: interrelationships between hemodynamics and blood volume after acute blood loss. Ann Surg 178: 87-94.
63. Prist R, Rocha-e-Silva M, Scalabrini A, Coelho IJ, Franca ES, et al. (1994) A quantitative analysis of transcapillary refill in severe hemorrhagic hypotension in dogs. Shock 1: 188-195.
64. Isbister JP (1997) Physiology and pathophysiology of blood volume regulation. Transfus Sci 18: 409-423.
65. Cap AP, Spinella PC, Borgman MA, Blackbourne LH, Perkins JG (2012) Timing and location of blood product transfusion and outcomes in massively transfused combat casualties. J Trauma Acute Care Surg 73: S89-94.
66. Holcomb JB, Wade CE, Michalek JE, Chisholm GB, Zarzabal LA, et al. (2008) Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 248: 447-458.
67. Mosnier LO, Zampolli A, Kerschen EJ, Schuepbach RA, Banerjee Y, et al. (2009) Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood 113: 5970-5978.
68. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW (2001) Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276: 11199-11203. (Pubitemid 38089304)
69. Mosnier LO, Zlokovic BV, Griffin JH (2007) The cytoprotective protein C pathway. Blood 109: 3161-3172. (Pubitemid 46572500)
70. Espana F, Gruber A, Heeb MJ, Hanson SR, Harker LA, et al. (1991) In vivo and in vitro complexes of activated protein C with two inhibitors in baboons. Blood 77: 1754-1760.